Role for Erk and NF-κB in nuclear elongation and CD69 expression.

<p>a) Normalized histogram showing C_L/C_S values in activated T-cells in M− and M+ conditions in control and cells treated with U0126 or IKK2 inhibitors (n = 200). The red line is used as a cut-off that marks round cells. b) Fraction of cells positive for CD69 in control or in presence of U0126 or IKK2 inhibitors. **p<0.005. Statistical significance is calculated with respect to control samples (M− or M+). c) Fold-change in levels of pERK in T-cells in control (M− and M+) and cytoD treated (M− and M+) conditions (N = 3, mean±s.d.). Inset- representative Western blot for pErk (top) and tubulin (bottom). Lane 1: untreated; 2: M−; 3: M-cytoD+; 4: untreated; 5: M+; 6: M+cytoD+. Statistical significance is calculated for cytoD treated samples with respect to their corresponding control. *p<0.05; **p<0.005. c) Fold change in levels of phosphorylated p130Cas in M− and M+ conditions (N = 3, mean ±s.d.). Inset- representative Western blot for phosphorylated p130Cas (top) and tubulin (bottom). lane 1: untreated; 2: M−; 3: M+. Statistical significance is calculated with respect to M−. **p<0.005.